Astera Labs Inc (ALAB) concluded trading on Wednesday at a closing price of $68.82, with 4.75 million shares of worth about $327.13 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 80.96% during that period and on March 12, 2025 the price saw a gain of about 4.19%. Currently the company’s common shares owned by public are about 162.02M shares, out of which, 120.66M shares are available for trading.
Stock saw a price change of 0.36% in past 5 days and over the past one month there was a price change of -33.37%. Over the period of past 52 weeks, stock dropped to lowest price of $36.22 but also hit the highest price of $147.39 during that period. The average intraday trading volume for Astera Labs Inc shares is 5.45 million. The stock is currently trading -11.15% below its 20-day simple moving average (SMA20), while that difference is down -32.23% for SMA50 and it goes to -9.84% lower than SMA200.
Astera Labs Inc (NASDAQ: ALAB) currently have 162.02M outstanding shares and institutions hold larger chunk of about 58.33% of that.
The stock has a current market capitalization of $11.16B and its 3Y-monthly beta is at 0.08. It has posted earnings per share of -$0.54 in the same period. It has Quick Ratio of 11.21 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALAB, volatility over the week remained 8.60% while standing at 8.48% over the month.
Stock’s fiscal year EPS is expected to rise by 50.02% while it is estimated to increase by 36.10% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Northland Capital on January 28, 2025 offering an Outperform rating for the stock and assigned a target price of $120 to it. Coverage by Morgan Stanley stated Astera Labs Inc (ALAB) stock as an Equal-weight in their note to investors on January 21, 2025, suggesting a price target of $142 for the stock. On January 02, 2025, Northland Capital Downgrade their recommendations, while on November 18, 2024, Citigroup Initiated their ratings for the stock with a price target of $120. Stock get an Overweight rating from Morgan Stanley on September 04, 2024.
